/
/
/

Alivus Life Sciences Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020
₹640 Cr₹689 Cr₹673 Cr₹588 Cr₹602 Cr₹650 Cr₹642 Cr₹507 Cr₹589 Cr₹537 Cr₹573 Cr₹595 Cr₹578 Cr₹621 Cr₹541 Cr₹509 Cr₹490 Cr₹514 Cr₹522 Cr₹562 Cr₹525 Cr₹467 Cr₹500 Cr₹521 Cr₹397 Cr
₹22 Cr₹23 Cr₹14 Cr₹15 Cr₹9 Cr₹10 Cr₹10 Cr₹9 Cr₹5 Cr₹3 Cr₹2 Cr₹5 Cr₹2 Cr₹3 Cr₹7 Cr₹10 Cr₹9 Cr₹5 Cr₹4 Cr₹2 Cr₹4 Cr₹34 L₹37 L₹1 L₹2 Cr
₹663 Cr₹712 Cr₹687 Cr₹603 Cr₹611 Cr₹660 Cr₹652 Cr₹515 Cr₹594 Cr₹540 Cr₹574 Cr₹601 Cr₹580 Cr₹624 Cr₹547 Cr₹519 Cr₹499 Cr₹519 Cr₹526 Cr₹564 Cr₹529 Cr₹468 Cr₹501 Cr₹521 Cr₹399 Cr
₹449 Cr₹495 Cr₹461 Cr₹427 Cr₹447 Cr₹467 Cr₹467 Cr₹388 Cr₹444 Cr₹410 Cr₹413 Cr₹441 Cr₹398 Cr₹426 Cr₹406 Cr₹376 Cr₹353 Cr₹381 Cr₹386 Cr₹404 Cr₹373 Cr₹306 Cr₹354 Cr₹402 Cr₹267 Cr
₹234 Cr₹237 Cr₹245 Cr₹194 Cr₹181 Cr₹209 Cr₹201 Cr₹143 Cr₹165 Cr₹145 Cr₹174 Cr₹172 Cr₹195 Cr₹209 Cr₹152 Cr₹154 Cr₹156 Cr₹147 Cr₹150 Cr₹169 Cr₹164 Cr₹170 Cr₹155 Cr₹127 Cr₹140 Cr
₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹46 L₹34 L₹35 L₹36 L₹39 L₹40 L₹40 L₹12 L₹16 L₹13 L₹14 L₹13 L₹6 L₹7 Cr₹21 Cr₹21 Cr₹22 Cr₹22 Cr₹23 Cr
₹212 Cr₹216 Cr₹198 Cr₹174 Cr₹163 Cr₹191 Cr₹185 Cr₹127 Cr₹150 Cr₹130 Cr₹161 Cr₹159 Cr₹182 Cr₹198 Cr₹141 Cr₹144 Cr₹146 Cr₹138 Cr₹140 Cr₹153 Cr₹135 Cr₹141 Cr₹125 Cr₹97 Cr₹108 Cr
₹160 Cr₹163 Cr₹150 Cr₹130 Cr₹122 Cr₹142 Cr₹137 Cr₹95 Cr₹111 Cr₹98 Cr₹119 Cr₹119 Cr₹135 Cr₹146 Cr₹105 Cr₹107 Cr₹109 Cr₹99 Cr₹104 Cr₹115 Cr₹101 Cr₹105 Cr₹93 Cr₹72 Cr₹81 Cr

Share Price Live Stats

Open (₹)1,418.90
Volume (₹)1.70 L
High (₹)1,446.90
Upper Circuit1,702.50
Low (₹)1,356.40
Lower Circuit1,135.10
Prev Close1,418.80
52W High (₹)1,493.80
Price1,366.30
52W Low (₹)819.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)17415.70 Cr
Div. Yield (%)0.35
PE Ratio28.88
Debt to Equity0.00
Price to Book3.60
Book Value270.90
EPS (TTM)49.12
Face Value2.00
ROE (%)18.41

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
ALIVUSNSE
LTP
1W Low
1W High
Market cap (₹)
1899-21 (-1.09%)
1895
1984.80
4,56,833Cr
9100-139 (-1.50%)
9087
9467
2,45,426Cr
4857-193 (-3.82%)
4823
5066
1,87,320Cr
1120-71 (-5.96%)
1120
1187
1,13,217Cr
1385-38.5 (-2.70%)
1375.50
1426.10
1,12,212Cr
1840-98.5 (-5.08%)
1811.70
1949
1,01,155Cr
2110-61.5 (-2.83%)
2100.60
2192
97,626Cr
2327.9-55 (-2.31%)
2317
2419.20
96,859Cr
1151-27 (-2.29%)
1151
1179.90
96,406Cr
1653.1+7.8 (0.47%)
1622.60
1717
93,614Cr
1366.3+16.1 (1.19%)
1352
1493.80
17,416Cr

Key Highlights of Alivus Life Sciences Ltd’s P&L

In 2026-03-31, Alivus Life Sciences Ltd reported total revenue of ₹2551.83Cr, compared with ₹2386.88Cr in 2025-03-31, reflecting Alivus Life Sciences Ltd turnover.

Depreciation was ₹75.36Cr and finance costs were ₹5.37Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹751.31Cr in 2026-03-31 as compared to ₹654.13Cr in 2025-03-31.

Net Profit (PAT) was ₹564.48Cr in 2026-03-31 compared with ₹485.63Cr in 2025-03-31.

Earnings per share (EPS) were ₹45.99 in 2026-03-31, compared with ₹39.63 in 2025-03-31.